Laboratory of Cancer Precision Medicine, the First Hospital of Jilin University, Changchun, Jilin, China.
Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China.
Expert Opin Ther Targets. 2021 Nov;25(11):965-986. doi: 10.1080/14728222.2021.2011206. Epub 2021 Dec 30.
Ferroptosis, a form of programmed cell death, is mediated primarily by lipid peroxidation via a unique iron-dependent process. The mechanisms of ferroptosis involve the metabolisms of amino acids, irons, and lipids, and the regulation of antioxidant systems. Evidence supports the roles of ferroptosis in cancer, while metabolic reprogramming (a hallmark of cancer) renders tumor cells highly vulnerable to ferroptosis and thus provides a rationale for ferroptosis-targeted therapy for cancer.
This article examines the current understanding of the mechanisms and related signaling pathways involving ferroptosis; it focuses on novel targets in cancer and its treatment and drug resistance. The development of ferroptosis-targeted therapy, especially in combination with conventional or non-conventional therapies, are considered with dilemmas and key questions in this research area.
An increasing number of potential targets and ferroptosis inducers (FINs) have been identified to treat cancer. However, no specific FIN has entered clinical trials thus far, likely due to poor efficacy and high toxicity . Thus, new FINs with high selectivity and bioavailability are required to target tumor cells more specifically and potently. Particularly, the combination of FINs with chemotherapy, radiotherapy, targeted therapy, and immunotherapy warrants clinical investigation in the future.
铁死亡是一种程序性细胞死亡形式,主要通过独特的铁依赖性过程介导脂质过氧化。铁死亡的机制涉及氨基酸、铁和脂质的代谢以及抗氧化系统的调节。有证据表明铁死亡在癌症中起作用,而代谢重编程(癌症的一个标志)使肿瘤细胞极易发生铁死亡,从而为针对癌症的铁死亡靶向治疗提供了依据。
本文探讨了铁死亡涉及的机制和相关信号通路的最新理解;重点关注癌症及其治疗和耐药性中的新靶点。本文还考虑了铁死亡靶向治疗的发展,特别是与传统或非传统治疗相结合的发展,以及在这一研究领域存在的困境和关键问题。
为了治疗癌症,已经确定了越来越多的潜在靶点和铁死亡诱导剂(FINs)。然而,到目前为止,还没有特定的 FIN 进入临床试验,可能是由于疗效差和毒性高。因此,需要具有高选择性和生物利用度的新型 FINs,以更特异性和更有效地靶向肿瘤细胞。特别是 FINs 与化疗、放疗、靶向治疗和免疫治疗的联合应用值得在未来进行临床研究。